Coexpression of the cannabinoid receptor type 1 with dopamine and serotonin receptors in distinct neuronal subpopulations of the adult mouse forebrain

被引:238
作者
Hermann, H [1 ]
Marsicano, G [1 ]
Lutz, B [1 ]
机构
[1] Max Planck Inst Psychiat, Grp Mol Genet Behavior, D-80804 Munich, Germany
关键词
cannabinoids; colocalization; in situ hybridization; cross-talk; neurotransmitter systems;
D O I
10.1016/S0306-4522(01)00509-7
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
The cannabinoid receptor type 1 (CB1) displays unusual properties, including the dual capacity to inhibit or stimulate adenylate cyclase and a brain density considerably higher than the majority of G protein-coupled receptors. Together with overlapping expression patterns of dopamine and serotonin receptors this suggests a potential of CB1 to modulate the function of the dopamine and serotonin system. Indeed, pharmacological studies provide evidence for cross-talks between CB1 and receptors of these neurotransmitter systems. In trying to obtain further insights into possible functional and/or structural interactions between CB1 and the dopamine receptors and the serotonin receptors, we performed double-label in situ hybridization at the cellular level on mouse forebrain sections by combining a digoxigenin-labelled riboprobe for CB1 with S-35-labelled riboprobes for dopamine receptors D1 and D2. and for serotonin receptors 5-HT1B and 5-HT3, respectively. As a general rule, we found that CB1 colocalizes with D1, D2 and 5-HT1B only in low-CB1-expressing cells which are principal projecting neurons, whereas CB1 coexpression with 5-HT3 was also observed in high-CB1-expressing cells which are considered to be mostly GABAergic. In striatum and olfactory tubercle, CB1 is coexpressed to a high extent with D1, D2 and 5-HT1B. Throughout the hippocampal formation, CB1 is coexpressed with D2, 5-HT1B and 5-HT3. In the neocortex. coexpression was detected only with 5-HT1B and 5-HT3. In summary a distinct pattern is emerging for the cannabinoid system with regard to its colocalization with dopamine and serotonin receptors and, therefore. it is likely that different mechanisms underlie its cross-talk with these neurotransmitter systems. (C) 2002 IBRO. Published by Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:451 / 460
页数:10
相关论文
共 48 条
  • [1] Anatomical and physiological evidence for D1 and D2 dopamine receptor colocalization in neostriatal neurons
    Aizman, O
    Brismar, H
    Uhlén, P
    Zettergren, E
    Levey, AI
    Forssberg, H
    Greengard, P
    Aperia, A
    [J]. NATURE NEUROSCIENCE, 2000, 3 (03) : 226 - 230
  • [2] FUNCTIONAL ARCHITECTURE OF BASAL GANGLIA CIRCUITS - NEURAL SUBSTRATES OF PARALLEL PROCESSING
    ALEXANDER, GE
    CRUTCHER, MD
    [J]. TRENDS IN NEUROSCIENCES, 1990, 13 (07) : 266 - 271
  • [3] Bonhaus DW, 1998, J PHARMACOL EXP THER, V287, P884
  • [4] Oligomerization of G-protein-coupled transmitter receptors
    Bouvier, M
    [J]. NATURE REVIEWS NEUROSCIENCE, 2001, 2 (04) : 274 - 286
  • [5] The effects of anandamide on memory consolidation in mice involve both D1 and D2 dopamine receptors
    Castellano, C
    Cabib, S
    Palmisano, A
    Di Marzo, V
    Puglisi-Allegra, S
    [J]. BEHAVIOURAL PHARMACOLOGY, 1997, 8 (08): : 707 - 712
  • [6] ISOLATION AND STRUCTURE OF A BRAIN CONSTITUENT THAT BINDS TO THE CANNABINOID RECEPTOR
    DEVANE, WA
    HANUS, L
    BREUER, A
    PERTWEE, RG
    STEVENSON, LA
    GRIFFIN, G
    GIBSON, D
    MANDELBAUM, A
    ETINGER, A
    MECHOULAM, R
    [J]. SCIENCE, 1992, 258 (5090) : 1946 - 1949
  • [7] Enhanced levels of endogenous cannabinoids in the globus pallidus are associated with a reduction in movement in an animal model of Parkinson's disease
    Di Marzo, V
    Hill, MP
    Bisogno, T
    Crossman, AR
    Brotchie, JM
    [J]. FASEB JOURNAL, 2000, 14 (10) : 1432 - 1438
  • [8] Endocannabinoids: endogenous cannabinoid receptor ligands with neuromodulatory action
    Di Marzo, V
    Melck, D
    Bisogno, T
    De Petrocellis, L
    [J]. TRENDS IN NEUROSCIENCES, 1998, 21 (12) : 521 - 528
  • [9] Egertová M, 2000, J COMP NEUROL, V422, P159, DOI 10.1002/(SICI)1096-9861(20000626)422:2<159::AID-CNE1>3.0.CO
  • [10] 2-1